I mean, Marty Macri, the FDA commissioner, has talked about trying to broaden the scope of those policies to try to enable rare disease drugs to get to patients more quickly. This particular drug, though, has attracted scrutiny in the past because of the process that it went through. It's, you know, been sort of written about and maligned. So I think this is a sort of test case for the scope of how much they want to intervene … (07:23–07:29)
CLAIM
Asserts that a specific drug has been scrutinized due to its approval process.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
